Genomate Health

Genomate Health Genomate Health is a digital health company that develops computational solutions for personalized medicine.

We’re proud to see our story featured in Telex.hu highlighting how Hungarian innovation is shaping the future of cancer ...
01/28/2026

We’re proud to see our story featured in Telex.hu highlighting how Hungarian innovation is shaping the future of cancer care on the global stage: https://telex.hu/g7/adat/2026/01/28/oncompass-petak-istvan-genomate-budapest-boston-rakdiagnosztika

Both Genomate Health and Oncompass Medicine started with a bold vision: to understand each tumor at the molecular level and help clinicians make more informed, personalized treatment decisions. Today, that vision continues as a united, international company serving patients and clinicians across Europe and the US.

How can we turn complex tumor profiles into clear, evidence-based treatment decisions?On January 30, Genomate Health Fou...
01/28/2026

How can we turn complex tumor profiles into clear, evidence-based treatment decisions?

On January 30, Genomate Health Founder and CSO Istvan Petak MD, PhD will speak at the Center for Cancer Research Impromptu Seminar Series, hosted by Gergely Szakacs, to explore this question and more.

Join us to learn how structured, algorithmic tools are helping improve consistency, confidence, and outcomes in precision oncology.

Sign up here: https://lnkd.in/dQmsreTp

Cervical cancer is one of the most preventable and treatable cancers, if caught early. Screening, HPV vaccination, and t...
01/22/2026

Cervical cancer is one of the most preventable and treatable cancers, if caught early. Screening, HPV vaccination, and timely care have changed the outlook for millions. But progress isn’t equal everywhere.

Too many people are still diagnosed late. Too many face barriers to testing or lack access to care tailored to the biology of their cancer. At Genomate Health, we focus on the moments after diagnosis, helping oncologists make evidence-based treatment decisions, especially when standard options fall short.

This month, we stand with the clinicians, researchers, and advocates working to ensure everyone has access to the tools to eliminate cervical cancer.

Today marks a major milestone for Genomate Health. We are thrilled to announce we’ve acquired Oncompass Medicine, a Euro...
01/14/2026

Today marks a major milestone for Genomate Health. We are thrilled to announce we’ve acquired Oncompass Medicine, a European pioneer in precision oncology with more than two decades of clinical and diagnostic leadership.

This acquisition:
↘ Establishes Genomate Health’s European operational and diagnostics base
↘ Expands our clinical, laboratory, and R&D capabilities in Budapest
↘ Integrates deep molecular diagnostics expertise with computational reasoning
↘ Accelerates global deployment of clinically validated precision oncology solutions

Oncompass Medicine will continue operating in Hungary as Oncompass Medicine, a Genomate Health company: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/genomate-health-expands-global-footprint-with-acquisition-of-oncompas-1113068

Together, we are building a unified precision oncology platform that transforms complex molecular data into clinically relevant treatment decisions, at scale.

By the end of 2025, Genomate Health had crossed a critical threshold. Genomate® had been scientifically validated, deplo...
01/13/2026

By the end of 2025, Genomate Health had crossed a critical threshold. Genomate® had been scientifically validated, deployed in early clinical use, and engaged with regulators as a new category of precision oncology software.

As we move into 2026, the focus shifts from proving what is possible to scaling what works: expanding clinical adoption, advancing regulatory pathways, and continuing to build evidence that supports equitable access to precision oncology.

Read all about our 2025 here: https://www.genomate.health/news-article/genomate-health-2025-in-review

As we close out the year, we pause to appreciate the progress made in cancer care and the people who make that progress ...
12/24/2025

As we close out the year, we pause to appreciate the progress made in cancer care and the people who make that progress real, every day.

Wishing you a joyful holiday season and a healthy, successful year ahead 💚

- The Genomate Health team

Our CEO Nabil Hafez will be in San Francisco during JPM Healthcare Week 2026, and he’s looking forward to connecting wit...
12/23/2025

Our CEO Nabil Hafez will be in San Francisco during JPM Healthcare Week 2026, and he’s looking forward to connecting with peers, partners, and investors along the way.

At Genomate Health, we’re focused on making precision oncology more consistent, reproducible, and actionable using computational reasoning. If you’re working on clinical decision support, biomarker-driven therapy selection, or thinking about how to scale precision medicine beyond academic centers, we’d love to work together.

Learn more and book some time to chat here: https://www.genomate.health/event/genomate-health-at-jpm-2026

A new real-world study in Cancer Medicine (2025) shows both the promise (and the limits) of precision oncology.Molecular...
12/19/2025

A new real-world study in Cancer Medicine (2025) shows both the promise (and the limits) of precision oncology.

Molecular Tumor Boards recommended biomarker-matched therapies for 59% of profiled patients, yet only 17% ultimately received them. When patients did gain access, the impact was meaningful: 41% achieved longer progression-free survival compared with their previous line of treatment.

The message is clear. Biomarker-guided care works, but access doesn’t scale.

This is the gap Genomate addresses. By translating complex molecular data into actionable, computational reasoning–driven treatment insights, Genomate extends molecular decision support beyond academic centers, bringing precision oncology to every patient, everywhere.

Read the study: https://onlinelibrary.wiley.com/doi/10.1002/cam4.71119

By 2030, the world will see more than 24 million new cancer cases.That number is rising each year, not just because of a...
12/09/2025

By 2030, the world will see more than 24 million new cancer cases.

That number is rising each year, not just because of aging populations, but because we’re getting better at detection. Oncologists will face more complexity. More data. More patients needing fast, confident treatment decisions. And with that progress comes a new kind of pressure: how do we match each case to the right treatment, when time, evidence, and access are limited?

At Genomate Health, we’re focused on helping meet that challenge, by turning complex molecular data into clear, prioritized treatment options. Our computational reasoning platform supports clinical teams in making decisions that are evidence-based, scalable, and aligned with each patient’s biology.

As cancer care evolves, so must the tools we use to deliver it.

Explore the IARC Global Cancer Observatory projections: https://gco.iarc.fr/tomorrow/en/dataviz/isotype?years=2030&single_unit=500000

Grief is part of cancer care.Sometimes it arrives with loss.Sometimes with fear.Sometimes in the quiet moments after har...
12/03/2025

Grief is part of cancer care.
Sometimes it arrives with loss.
Sometimes with fear.
Sometimes in the quiet moments after hard decisions.

During Grief Awareness Week, we acknowledge something that often goes unsaid: treating cancer is not only about clinical outcomes. It’s about the patients, families and care teams carrying the emotional weight that comes with uncertainty, change, and loss.

At Genomate Health, we focus on clarity in complex moments. But we also recognize that no amount of data removes the human experience of grief.

To those living with it, moving through it, or holding space for others: our thoughts are with you.

A new study published in ESMO Open (2025) highlights why personalized cancer treatment matters. Patients whose therapies...
11/24/2025

A new study published in ESMO Open (2025) highlights why personalized cancer treatment matters. Patients whose therapies were matched to their tumor’s molecular profile lived nearly three times longer than those who didn’t receive matched treatment.

Even when the scientific evidence wasn’t yet considered the strongest, personalized treatment based on genetic markers made a clear difference.

At Genomate Health, we help make this kind of care more accessible. Our platform analyzes the full molecular profile of a tumor and helps clinicians prioritize treatment options that align with the biology of the disease, not just the diagnosis. Even in complex cases.

Read the study: https://www.esmoopen.com/article/S2059-7029%2825%2901640-0/fulltext

Pancreatic cancer doesn’t give us much time.Symptoms are often subtle. Diagnosis is often late. And treatment decisions ...
11/21/2025

Pancreatic cancer doesn’t give us much time.
Symptoms are often subtle. Diagnosis is often late. And treatment decisions can become urgent (and complex) very quickly.

At Genomate Health, we focus on helping clinicians make sense of that complexity. When treatment paths aren’t clear, our goal is to help uncover the next best step, based on the full molecular profile of the tumor, not just the diagnosis.

But before precision, there’s prevention.
If you notice ongoing fatigue, unexplained weight loss, digestive changes, or persistent pain, don’t dismiss it. Talk to your doctor.

Address

Cambridge, MA

Website

Alerts

Be the first to know and let us send you an email when Genomate Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Genomate Health:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category